Ransi Somaratne
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Pharmaceutical Economics and Policy, Health Systems, Economic Evaluations, Quality of Life, Cancer, Lipids, and Metabolism, Atherosclerosis and Cardiovascular Diseases
Most-Cited Works
- → Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients(2016)1,113 cited
- → PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial(2014)742 cited
- → Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial(2017)665 cited
- → Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia(2014)493 cited
- → AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy(2013)175 cited
- → Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease(2017)143 cited
- → Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data(2016)143 cited
- → Effect of Evolocumab on Coronary Plaque Composition(2018)134 cited
- → Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin(2017)104 cited
- → Traditional and New Composite Endpoints in Heart Failure Clinical Trials: Facilitating Comprehensive Efficacy Assessments and Improving Trial Efficiency(2016)93 cited